Business Context and Reporting Period
On August 1, 2026, Indivior Pharmaceuticals, Inc. (Indivior) entered into an Agreement and Plan of Merger with Supernus Pharmaceuticals, Inc. (Supernus). Under the terms of the agreement, a wholly-owned subsidiary of Indivior will merge with and into Supernus, with Supernus surviving as a wholly-owned subsidiary of Indivior. Following the transaction, Indivior will be renamed Supernus, Inc. (the "Combined Company").
Key Financial Metrics and Transaction Terms
- Exchange Ratio: Each outstanding Supernus share will be converted into 1.5401 shares of Indivior common stock.
- Ownership Structure: Upon completion, Indivior stockholders are expected to own approximately 56.5% of the Combined Company, while Supernus stockholders will own approximately 43.5% on a fully diluted basis.
- Special Dividend: Indivior will declare a special cash dividend of $1,000,000,000 payable to Indivior shareholders of record immediately prior to the Effective Time.
- Financing: Indivior has secured a commitment from Citibank, N.A. for a senior secured term loan facility of $650 million to support the transaction.
- Equity Awards: Supernus restricted stock units (RSUs) and performance stock units (PSUs) will convert to Indivior RSUs. Supernus options will convert to Indivior options with adjusted share counts and exercise prices based on the Exchange Ratio.
Material Changes and Governance
The transaction represents a material change in corporate structure and leadership. The Combined Company Board will consist of eight members, split evenly with four nominees from each company's current board. Jack A. Khattar will serve as Chief Executive Officer, and Timothy C. Dec will serve as Chief Financial Officer. The Combined Company will trade on Nasdaq under the ticker symbol "SUPN."
Guidance, Risks, and Contingencies
Conditions to Closing: The merger is subject to customary conditions, including stockholder approval from both Indivior and Supernus, regulatory approvals (including expiration of HSR Act waiting periods), and the absence of any law or order prohibiting the transaction.
Termination Fees:
- Indivior must pay Supernus a termination fee of $174.0 million under specific circumstances, including a change in Indivior's recommendation, a Superior Proposal, or failure to close due to Indivior's breach.
- Supernus must pay Indivior a termination fee of $101.0 million under similar circumstances regarding a change in recommendation, a Superior Proposal, or failure to close due to Supernus's breach.
Risks: The filing highlights risks regarding the failure to obtain stockholder or regulatory approvals, the possibility of a competing proposal, the fixed exchange ratio not adjusting for market price changes, and the impact of the $1 billion special dividend and associated debt on the Combined Company's liquidity.
Investor Verification Checklist
- Verify the approval status of the merger by both Indivior and Supernus stockholders.
- Confirm the receipt of all necessary regulatory and antitrust approvals.
- Review the upcoming joint proxy statement/prospectus (Form S-4) for detailed financial projections and risk factors.
- Assess the impact of the $1 billion special dividend and $650 million term loan on the Combined Company's future debt load and liquidity.
- Monitor for any competing proposals that could trigger termination fees or alter the transaction structure.